Stem cell–based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection
Animal Models and Experimental Medicine · 2026-07 · 9 (7) · 1277-1291
DOI: 10.1002/ame2.70211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 09.05.2026. Verfasst von Zifan Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Primate Biomedical Research; Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunmi…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Cell Differentiation, Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Yunnan Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Transplantation of insulin‐producing cells derived from pluripotent stem cells represents a highly promising approach for the radical treatment of type 1 diabetes (T1D). Informed by a comprehensive understanding of fetal pancreatic development, directed differentiation protocol for generating pancreatic β cells from pluripotent stem cells has been established and has achieved considerable advances, enabling the production of mature, fully functional β cells that closely recapitulate the characteristics of native pancreatic β cells. Preclinical studies have shown that the transplantation of stem cell–derived islets (SC‐islets) reverses hyperglycemia in both mouse and nonhuman primate models, with a favorable safety profile. Early‐phase clinical trials have further corroborated the safety and efficacy of this approach, a subset of patients with long‐standing T1D achieved insulin independence, described as a “functional cure”, with no serious adverse events of clinical significance reported. Despite these encouraging results, substantial challenges remain. With respect to differentiation protocols, insufficient functional maturity, pronounced cellular heterogeneity, significant batch‐to‐batch variability, and the challenges of large‐scale manufacturing represent the principal unresolved limitations. Of particular concern, immune rejection remains a critical barrier even after the transplantation of autologous SC‐islets, necessitating continued reliance on immunosuppressive therapy. Cell encapsulation and gene editing strategies have emerged as potential approaches to overcome this immunological barrier. In this review, we discuss strategies for obtaining insulin‐producing cells from diverse cellular sources, summarize the latest advances in stem cell–based diabetes therapy, and propose future research directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Primate Biomedical Research; Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, Yunnan, China.
- Yunnan Key Laboratory of Primate Biomedical Research, Kunming, Yunnan, China.
- Southwest United Graduate School, Kunming, Yunnan, China.
ORCID-Profile: Yuyu Niu
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Yunnan Province
- Xingdian Talent Support Plan of Yunnan Province, China
- National Key Research and Development Program of China
Zitieren
APA
Li, Z., Kang, Y., & Niu, Y. (2026). Stem cell–based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection. Animal Models and Experimental Medicine, 9(7), 1277-1291. https://doi.org/10.1002/ame2.70211
Vancouver
Li Z, Kang Y, Niu Y. Stem cell–based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection. Animal Models and Experimental Medicine. 2026;9(7):1277-1291. doi:10.1002/ame2.70211
BibTeX
@article{Li2026,
author = {Li, Zifan and Kang, Yu and Niu, Yuyu},
title = {Stem cell–based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection},
journal = {Animal Models and Experimental Medicine},
year = {2026},
volume = {9},
number = {7},
pages = {1277--1291},
doi = {10.1002/ame2.70211}
}
EUVIMED